Phoenix Roadshow 2025 – Copenhagen Live Events Phoenix Roadshow 2025 – Copenhagen CertaraJuly 2, 2025
Optimization of voriconazole dosage via population pharmacokinetic analysis based on the albumin-bilirubin (ALBI) score of patients with liver dysfunction Publication Optimization of voriconazole dosage via population pharmacokinetic analysis based on the albumin-bilirubin (ALBI) score of patients with liver dysfunction See how ALBI‑based PopPK modelling supports practical voriconazole dose reductions in liver dysfunction using Phoenix…CertaraJuly 2, 2025
The reference-scaled average bioequivalence (RSABE) approach Blog The reference-scaled average bioequivalence (RSABE) approach We examine the Reference-scaled Average Bioequivalence (RSABE) approach for generic drug development and how it…Ana HenryJuly 1, 2025
Bioequivalence study of two formulations of lurasidone film coated tablets in healthy subjects under fed conditions Publication Bioequivalence study of two formulations of lurasidone film coated tablets in healthy subjects under fed conditions Learn how fed‑condition crossover study confirms lurasidone bioequivalence and comparable safety using Phoenix WinNonlin.CertaraJuly 1, 2025
Impact of body weight on mycophenolic acid population pharmacokinetics in paediatric lupus nephritis: a pharmacogenomic integration study Publication Impact of body weight on mycophenolic acid population pharmacokinetics in paediatric lupus nephritis: a pharmacogenomic integration study Find out how PopPK modelling shows body weight is the key driver of MPA exposure…CertaraJuly 1, 2025
Certara Enhances Integral Data Repository with Powerful REST API Capabilities in Version 25.4.1 Announcement Certara Enhances Integral Data Repository with Powerful REST API Capabilities in Version 25.4.1 Radnor, PA – June 20, 2025 - Certara, Inc. (Nasdaq: CERT), a global leader in…CertaraJune 20, 2025
In Vivo PK-PD and Drug-Drug Interaction Study of Dorzagliatin for the Management of PI3Kα Inhibitor-Induced Hyperglycemia Publication In Vivo PK-PD and Drug-Drug Interaction Study of Dorzagliatin for the Management of PI3Kα Inhibitor-Induced Hyperglycemia Explore how dorzagliatin increases exposure and improves antitumor efficacy when combined with PI3Kα inhibitors, analysed…CertaraJune 19, 2025
Latest Phoenix PK/PD analysis & modeling platform release prioritizes efficiency, power Announcement Latest Phoenix PK/PD analysis & modeling platform release prioritizes efficiency, power June 16, 2025 RADNOR, PA – June 16, 2025 – Certara, Inc. (Nasdaq: CERT), a…CertaraJune 16, 2025
Modernizing NCA Workflows: The Power of ADNCA for Regulatory-Ready Pharmacokinetic Analysis On-Demand Webinar Modernizing NCA Workflows: The Power of ADNCA for Regulatory-Ready Pharmacokinetic Analysis CertaraJune 11, 2025
Assessment of the Effects of Fruquintinib on Cardiac Safety in Patients with Metastatic Colorectal Cancer Publication Assessment of the Effects of Fruquintinib on Cardiac Safety in Patients with Metastatic Colorectal Cancer The study, published in the Journal of Clinical Pharmacology, evaluates the cardiac safety of fruquintinib,…CertaraJune 8, 2025